Skip to search formSkip to main contentSkip to account menu

golimumab

A human monoclonal antibody directed against the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-a) with immunosuppressive activity… 
National Institutes of Health

Related topics

Related topics

11 relations
0.5 ML golimumab 100 MG/ML Auto-Injector [Simponi]0.5 ML golimumab 100 MG/ML Prefilled Syringe1 ML golimumab 100 MG/ML Auto-Injector1 ML golimumab 100 MG/ML Auto-Injector [Simponi]

Broader (1)

Monoclonal Antibodies

Narrower (1)

Simponi

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
The introduction of biological therapies into clinical practice has dramatically modified the natural history of chronic… 
2017
2017
Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study
Anti‐tumour necrosis factor (TNF) agents have improved the care of Crohn's disease (CD). After the first anti‐TNF discontinuation… 
2016
2016
Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points
The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) have defined remission using… 
2014
2014
Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry
We read with great interest the recent article by Fleischmann et al which reports a post hoc analysis of five rheumatoid… 
Highly Cited
2013
Highly Cited
2013
Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial
Objective To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. Design This… 
Review
2010
Review
2010
Safety and efficacy of the tumor necrosis factor antagonists.
2010
2010
Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.
AIMS To develop a population pharmacokinetic (PK) model of subcutaneously administered golimumab, a human anti-tumor necrosis… 
Review
2010
Review
2010
Golimumab for rheumatoid arthritis.
BACKGROUND Golimumab is a humanized inhibitor of Tumor necrosis factor-alpha, recently approved by the Food and Drug… 
2010
2010
A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate
The need for accurate exposure–response modeling is critical in the drug development process. Few methods are available for… 
2008
2008
When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?
The advent of biological agents in general and tumour necrosis factor (TNF) inhibitors in particular has dramatically changed the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)